Business Context and Reporting Period
This Form 8-K is a current report filed by Reneo Pharmaceuticals, Inc. (not Onkure Therapeutics, Inc.) on November 8, 2022. The filing serves to announce the Company's financial results for the third quarter ended September 30, 2022, along with other recent corporate updates. The detailed financial data is contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not present in the source text provided for this summary.
Material Changes
The filing indicates the reporting of Q3 2022 results and corporate updates. No specific material changes versus the prior comparable period are detailed in the text of this Form 8-K.
Guidance, Outlook, and Risks
The filing notes the issuance of a press release regarding financial results and corporate updates. The text explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that section. Consequently, specific guidance, outlook, management commentary, risks, or contingencies are not detailed in this document.
Investor Verification Checklist
- Verify the correct registrant name is Reneo Pharmaceuticals, Inc. (Ticker: RPHM), as the input metadata incorrectly listed "Onkure Therapeutics, Inc."
- Review Exhibit 99.1 (the Press Release) to obtain actual financial figures for the quarter ended September 30, 2022, as they are absent from the 8-K text.
- Confirm the status of the Company as an Emerging Growth Company as indicated by the checkmark in the filing.
- Note that the financial information in this filing is furnished and not deemed "filed" under Section 18 of the Exchange Act.